RU2003108745A - Способ получения гидратов оланзапина и превращение их в кристаллические формы оланзапина - Google Patents

Способ получения гидратов оланзапина и превращение их в кристаллические формы оланзапина Download PDF

Info

Publication number
RU2003108745A
RU2003108745A RU2003108745/04A RU2003108745A RU2003108745A RU 2003108745 A RU2003108745 A RU 2003108745A RU 2003108745/04 A RU2003108745/04 A RU 2003108745/04A RU 2003108745 A RU2003108745 A RU 2003108745A RU 2003108745 A RU2003108745 A RU 2003108745A
Authority
RU
Russia
Prior art keywords
methyl
olanzapine
thieno
hydrochloride
benzodiazepine
Prior art date
Application number
RU2003108745/04A
Other languages
English (en)
Russian (ru)
Inventor
Бучи Редди РЕГУРИ (IN)
Бучи Редди РЕГУРИ
Рамеш ЧАККА (IN)
Рамеш ЧАККА
Роберт КОПРОВСКИ (US)
Роберт КОПРОВСКИ
Original Assignee
Др. Редди`З Лабораториз Лтд. (In)
Др. Редди`З Лабораториз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Редди`З Лабораториз Лтд. (In), Др. Редди`З Лабораториз Лтд. filed Critical Др. Редди`З Лабораториз Лтд. (In)
Publication of RU2003108745A publication Critical patent/RU2003108745A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2003108745/04A 2000-08-31 2001-03-07 Способ получения гидратов оланзапина и превращение их в кристаллические формы оланзапина RU2003108745A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN711/MAS/2000 2000-08-31
IN709/MAS/2000 2000-08-31
IN709CH2000 2000-08-31
IN711CH2000 2000-08-31

Publications (1)

Publication Number Publication Date
RU2003108745A true RU2003108745A (ru) 2005-01-10

Family

ID=26324874

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003108745/04A RU2003108745A (ru) 2000-08-31 2001-03-07 Способ получения гидратов оланзапина и превращение их в кристаллические формы оланзапина

Country Status (12)

Country Link
EP (1) EP1313742A1 (sk)
JP (1) JP2004507548A (sk)
AU (1) AU2001243475A1 (sk)
BR (1) BR0114031A (sk)
CA (1) CA2420987A1 (sk)
CZ (1) CZ2003566A3 (sk)
HU (1) HUP0300875A3 (sk)
IL (1) IL154688A0 (sk)
NO (1) NO20030926L (sk)
RU (1) RU2003108745A (sk)
SK (1) SK2502003A3 (sk)
WO (1) WO2002018390A1 (sk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002340328A1 (en) * 2001-10-29 2003-05-12 Janet I. Cord Olanzapine dihydrate-ii a process for its preparation and use thereof
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
AU2002251329A1 (en) * 2002-04-25 2003-11-10 Generics (Uk) Limited Novel crystalline forms of celecoxib and other compounds
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
EP1575962A1 (en) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
DE602004014264D1 (de) 2003-12-22 2008-07-17 Teva Pharma Verfahren zur herstellung von olanzapin
AR047460A1 (es) * 2004-01-27 2006-01-18 Synthon Bv Proceso para la fabricacion de acetato de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (acetato de olanzapina)
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
WO2005080401A1 (en) * 2004-02-19 2005-09-01 Neuland Laboratories Limited Process for the preparation of olanzapine form 1 useful as antipsychotic drug
WO2005107375A2 (en) * 2004-05-06 2005-11-17 Matrix Laboratories Ltd Process for the preparation of olanzapine form-i
DE05783995T1 (de) * 2004-07-14 2007-10-11 Shasun Chemicals and Drugs Ltd., Chennai Verbessertes verfahren zur herstellung von form i aus olanzapin
EP1778649A4 (en) 2004-07-14 2008-09-10 Jubilant Organosys Ltd PROCESS FOR PREPARING A PURE FORM OF 2-METHYL-4- (4-METHYL-1-PIPERAZINYL) -10H-THIENO [2,3-B] [1,5] BENZODIAZEPINE
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006025065A1 (en) * 2004-08-31 2006-03-09 Lee Pharma Private Limited A process for the preparation of anhydrous olanzopine hydrochloride of form-1
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
SI1838716T1 (sl) * 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
WO2006102176A2 (en) * 2005-03-21 2006-09-28 Dr. Reddy's Laboratories Ltd. Process for preparing crystalline form i of olanzapine
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
EP2185566A2 (en) * 2007-05-15 2010-05-19 Generics Ýuk¨Limited Process for the purification of olanzapine
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
FI3466934T3 (fi) 2016-05-31 2024-04-23 Taiho Pharmaceutical Co Ltd Sulfonamidiyhdisteitä tai niiden suola ribonukleotidireduktaasin inhibiittoreina syövän hoitamiseksi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
AU720366B2 (en) * 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D

Also Published As

Publication number Publication date
CZ2003566A3 (cs) 2004-01-14
WO2002018390A1 (en) 2002-03-07
AU2001243475A1 (en) 2002-03-13
BR0114031A (pt) 2003-09-09
HUP0300875A3 (en) 2005-09-28
EP1313742A1 (en) 2003-05-28
CA2420987A1 (en) 2002-03-07
SK2502003A3 (en) 2004-03-02
IL154688A0 (en) 2003-09-17
NO20030926D0 (no) 2003-02-27
JP2004507548A (ja) 2004-03-11
NO20030926L (no) 2003-04-24
HUP0300875A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
RU2003108745A (ru) Способ получения гидратов оланзапина и превращение их в кристаллические формы оланзапина
KR101441930B1 (ko) 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
RU2266287C2 (ru) 2-арилимино-2,3-дигидротиазолы, способы их получения и фармацевтическая композиция, их содержащая
CA2432148A1 (en) Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient
CN104860651A (zh) 生态养生坭兴陶泥料及用其制作生态养生水杯的工艺
SU1189347A3 (ru) Способ получени производных эрголина
JPH05194527A (ja) ピラゾール環がアルキル化されたピラゾロキノリン類の製造中間体
KR20030068164A (ko) 우로-선택성 α1-아드레날린 수용체 차단제로 유용한1,4-이치환된 피페라진 유도체
RU2003100508A (ru) 5-аминоалкилпиразоло[4,3-d]пиримидины
EG19644A (en) Process for preparing of tricyclic amines as novel cholinesterase inhibitros
IL152390A0 (en) Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
KR19980064286A (ko) 다형태를 갖는 독사조신 메실레이트의 새로운 형태(제 1형)
CN101809021B (zh) 八氢-吡咯并[3,4-b]吡咯n-氧化物
PL1789412T3 (pl) Krystaliczna zasada alfuzosyny
WO2005107375A3 (en) Process for the preparation of olanzapine form-i
KR102220480B1 (ko) 클로피도그렐황산염의 제조방법 및 이를 포함하는 약학제제
RU2331607C2 (ru) Фарфоровая масса
KR100436504B1 (ko) 적층식 다색 두부 제조 방법
CZ290318B6 (cs) Thiazolochinolindioxid, farmaceutický přípravek jej obsahující, jeho pouľití a způsob přípravy
WO2015157360A1 (en) Processes to make protein kinase inhibitors
RU2334726C2 (ru) Фарфоровая масса
FI80679C (fi) Trans-( )-1-(alkyl eller allyl)-6-oxo- 7-alkoxikarbonyldekahydrokinoliner som aer anvaendbara som mellanprodukter vid framstaellning av som dopaminagonister anvaendbara pyrimido/4,5-g/ kinoliner.
US3920679A (en) Thienodiazepine compounds
CN115784707A (zh) 隐足建盏的制备工艺及其制备的隐足建盏
DK1076458T3 (da) Twin-konverter

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20050111